View Author
patient cancer study cisplatin treatment grade irinotecan toxicity phase administration response level pharmacokinetic chemotherapy cycle oncol effect etoposide schedule course infusion diarrhea neck cancer tumor table result analysis combination phase ii study verweij j disease range regimen trial sn -38 randomized 80 mg /m plasma -38 group cisplatin dose intensity concentration intensity topotecan pki 166 verweij inhibitor clearance 2 weeks sam 486 chapter activity phase i study amifostine dose level dose intensity carcinoma oncology side effects sam 486a high-dose cisplatin high-dose smoking stoter g cpt -11 non-small metabolite therapy dose levels agent neomycin mesothelioma radiotherapy nausea sample neurotoxicity delay brostallicin cell carcinoma serum
10 Most Recent Publications
|
Effects of methimazole on the elimination of irinotecan
(Article)
Bol, J.M. van der Visser, T.J. Loos, W.J. Jonge, M.J.A. de Wiemer, E.A.C. Aken, M.O. van Planting, A.S.Th. Schellens, J.H. Verweij, J. Mathijssen, R.H.J. |
2011-01-01
|
|
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan
(Article)
Bol, J.M. van der Mathijssen, R.H.J. Creemers, G.J.M. Planting, A.S.Th. Loos, W.J. Wiemer, E.A.C. Friberg, L.E. Verweij, J. Sparreboom, A. Jonge, M.J.A. de |
2010-01-15
|
|
The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases.
(Article)
Verhoef, C. Pool, A.E.M. van der Nuyttens, J.J.M.E. Planting, A.S.Th. Eggermont, A.M.M. Wilt, J.H.W. de |
2009-01-01
|
|
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
(Article)
Eskens, F.A.L.M. Mom, C.H. Vries, E. de Planting, A.S.Th. Gietema, J.A. Amelsberg, A. Huisman, H. Doorn, L. van Burger, H. Stopfer, P. Verweij, J. |
2008-01-15
|
|
Cigarette smoking and irinotecan treatment: Pharmacokinetic interaction and effects on neutropenia
(Article)
Bol, J.M. van der Mathijssen, R.H.J. Loos, W.J. Friberg, L.E. Schaik, R.H.N. van Jonge, M.J.A. de Planting, A.S.Th. Verweij, J. Sparreboom, A. Jonge, M.J.A. de |
2007-07-01
|
|
Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary (Br J Surg 2006; 93: 872-878) [8]
(Article)
Verhoef, C. Nuytens, J.J. Planting, A.S.Th. Wilt, J.H.W. de |
2007-02-01
|
|
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
(Article)
Jong, F.A. de Kehrer, D.F.S. Ruit, J.B. Verweij, J. Sparreboom, A. Jonge, M.J.A. de Mathijssen, R.H.J. Cremers, G.J. Bruijn, P. de Schaik, R.H.N. van Planting, A.S.Th. Gaast, A. van der Eskens, F.A.L.M. Janssen, J.T. |
2006-09-18
|
|
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
(Article)
Hoekstra, R. Dumez, H. Fidler, I.J. Oosterom, A.T. van Verweij, J. Eskens, F.A.L.M. Gaast, A. van der Planting, A.S.Th. Heus, G. de Sizer, K.C. Ravera, C. Vaidyanathan, S. Bucana, C. |
2005-10-01
|
|
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer
(Article)
Zuylen, L. van Mueller, C. Choi, L. Bootle, D. Verweij, J. Ledermann, J.A. Bridgewater, J. Sparreboom, A. Eskens, F.A.L.M. Bruijn, P. de Sklenar, I. Planting, A.S.Th. |
2004-01-01
|
|
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer
(Article)
Tije, A.J. ten Antonellini, A. Fiorentini, F. Tursi, J. Jonge, M.J.A. de Mantel, M. Hartman, C.M. Planting, A.S.Th. Stoter, G. Verweij, J. Sparreboom, A. Gaast, A. van der Fowst, C. |
2003-01-01
|
